title: Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4+T Cells following Latency Reversal.
abstract: Therapeutic strategies that target the latent HIV-1 reservoir in resting CD4+T cells of infected individuals are always administered in the presence of combination antiretroviral therapy. Using a primary cell of HIV-1 latency, we evaluated whether different antiviral drug classes affected latency reversal (as assessed by extracellular virus production) by anti-CD3/CD28 monoclonal antibodies or bryostatin 1. We found that the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine significantly decreased HIV-1 production, by ≥1 log.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Zerbato
authors.affiliation: Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia.|Department of Microbiology, Monash University, Clayton, Victoria, Australia.|Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.|School of Science, College of Science, Engineering and Health, RMIT University, Melbourne, Victoria, Australia.
authors.forename: Gilda
authors.initials: G
authors.lastname: Tachedjian
authors.affiliation: Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA nps2@pitt.edu.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Sluis-Cremer
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000914:Antibodies, Viral / Q000494:pharmacology; D048588:Benzoxazines / Q000494:pharmacology*; D054713:Bryostatins / Q000494:pharmacology*; D018106:CD28 Antigens / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D017252:CD3 Complex / Q000235:genetics / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000821:virology; D003521:Cyclopropanes; D015870:Gene Expression; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D061251:Primary Cell Culture; D000068696:Rilpivirine / Q000494:pharmacology*; D017735:Virus Latency / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D000276:Adjuvants, Immunologic; D000480:Alkynes; D019380:Anti-HIV Agents; D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D048588:Benzoxazines; D054713:Bryostatins; D018106:CD28 Antigens; D017252:CD3 Complex; D003521:Cyclopropanes; D007376:Interleukin-2; C046785:bryostatin 1; D000068696:Rilpivirine; C098320:efavirenz
keywords: HIV-1; NNRTIs; latency; persistence; reservoir